Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apaziquone Post-TURBT for Noninvasive Bladder Cancer
NCT00598806Phase 3Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Aug 2007
- Primary completion
- Jan 2012
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in bladder cancer comparing Apaziquone with Placebo (2 arms). Primary endpoint: Recurrence Rate at 2 Years. Started Aug 2007; status: completed.
02
Drugs
apaziquone
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00598806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00598806.